After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80-3·25) for scale 4 versus scale 3 and 4·60 (1·85-11·48) for scale 5-6 versus scale 3 for diffusion impairment; OR 0·88 (0·66-1·17) for scale 4 versus scale 3 and OR 1·77 (1·05-2·97) for scale 5-6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58-0·96) for scale 4 versus scale 3 and 2·69 (1·46-4·96) for scale 5-6 versus scale 3 for fatigue or muscle weakness. 2 key findings →
Design: cohort study
Participants: 94
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
The long-term use of NSAIDs may protect against Alzheimer's disease but not against vascular dementia. 3 key findings →
Design: cohort study
Participants: 6,989
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
However, the advisory did not apply to conventional antipsychotic medications; the risk of death with these older agents is not known. 1 key finding →
Design: cohort study
Participants: 22,890
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia. 5 key findings →
Design: cohort study
Participants: 27,259
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Individual statins were not significantly associated with risk of Parkinson's disease, rheumatoid arthritis, venous thromboembolism, dementia, osteoporotic fracture, gastric cancer, colon cancer, lung cancer, melanoma, renal cancer, breast cancer, or prostate cancer. 3 key findings →
Design: cohort study
Participants: 692
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
JAMA
·
2001-03-01
In women with menopausal symptoms, HRT may have specific cognitive effects, and future studies should target these effects. 3 key findings →
Design: meta-analysis
Evidence: high
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
The evidence base for treating a range of nonmotor symptoms in PD has grown substantially in recent years. 2 key findings →
Participants: 37
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
BMC Medicine
·
2025-02-24
We included 18740 patients (10 205 women [54.5%]; mean [SD] age, 78.2[7.4] years), of which 4271 (22.8%) received at least one prescription for an antidepressant. 5 key findings →
Design: cohort study
Participants: 18,740
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
The preponderance of epidemiologic and tissue compositional studies supports a protective effect of omega-3 EFA intake, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in mood disorders. 3 key findings →
Design: meta-analysis
Evidence: high
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
65/100
✓ Peer-reviewed
alzhub usefulness score 65 out of 100.
·
PloS one
·
2016-03-10
Periodontitis is common in the elderly and may become more common in Alzheimer's disease because of a reduced ability to take care of oral hygiene as the disease progresses. 5 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
64/100
✓ Peer-reviewed
alzhub usefulness score 64 out of 100.
·
Age and Ageing
·
2025-04-28
One million nine hundred twenty-five thousand, five hundred sixty-three individuals were included across the four databases with a median follow-up ranging from 5.6 to 8.4 years. 4 key findings →
Design: meta-analysis
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
62/100
✓ Peer-reviewed
alzhub usefulness score 62 out of 100.
·
JAMA
·
2002-07-01
Persistence with statin therapy in older patients declines substantially over time, with the greatest drop occurring in the first 6 months of treatment. 1 key finding →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Alzheimer's disease is associated with progressive cerebral atrophy, which can be seen on MRI with high resolution. 2 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
61/100
✓ Peer-reviewed
alzhub usefulness score 61 out of 100.
·
JAMA Neurology
·
2025-04-07
This study included 33 858 patients in the GLP-1RA vs other GLD cohort (mean age, 65 years; 53.1% female), 34 185 patients in the SGLT2i vs other GLD cohort (mean age, 65.8 years; 49.3% female), and 24 117 patients in the GLP-1RA vs SGLT2i cohort (mean age, 63.8 years; 51.7% female). 5 key findings →
Participants: 33
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
As randomised trials are not always feasible or practical, observational studies remain crucial for addressing many causal questions in the dementia prevention field. 1 key finding →
Design: cohort study
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting >1% of the population ≥65 years of age and with a prevalence set to double by 2030. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
This study suggests that estrogen replacement therapy may be useful for preventing or delaying the onset of Alzheimer disease in postmenopausal women. 4 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
During the 6534 person-years of follow-up (mean, 5.02 years per person), 440 subjects were diagnosed as having dementia, including 333 with Alzheimer disease. 3 key findings →
Participants: 1,301
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its prevalence is rapidly increasing due to extended lifespans. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
We show that semaglutide was associated with a significantly reduced risk of overall ADRD incidence with a hazard ratio ranging from 0.54 (0.49-0.59) compared with insulin, 0.67 (0.61-0.74) compared with metformin, to 0.80 (0.72-0.89) compared with older generation glucagon-like peptide-1 agonists (GLP-1RAs). 4 key findings →
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Mild cognitive impairment (MCI) is a recently described syndrome that is currently thought of as a transition phase between healthy cognitive ageing and dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
52/100
✓ Peer-reviewed
alzhub usefulness score 52 out of 100.
·
JAMA
·
1994-04-06
Among the 2446 patients who received tacrine in clinical trials, ALT levels greater than the upper limit of normal (ULN) occurred on at least one occasion in 1203 patients (49%), ALT levels greater than three times the ULN occurred in 621 patients (25%), and ALT levels greater than 20 times the ULN occurred in 40 patients (2%). 5 key findings →
Design: open-label trial
Participants: 2,446
Evidence: low
Full summary, score breakdown and related studies →
Original source
51/100
✓ Peer-reviewed
alzhub usefulness score 51 out of 100.
·
CNS spectrums
·
2019-01-17
Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects 10-15% of the population over the age of 65. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
The objective of this study was to describe the occurrence of HIV dementia and neuropsychological testing abnormalities in a new cohort of HIV-seropositive individuals at high risk for HIV dementia and to compare these results to a cohort before the advent of highly active antiretroviral therapy (HAART). 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Human gait depends on a complex interplay of major parts of the nervous, musculoskeletal and cardiorespiratory systems. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 34,180 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.